Notizie e Video - EUROBIO-SCIENTIFIC - Inglese

EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segment Development of Eurobio Scientific proprietary product portfolio Increase of international exposure Paris, 7 th May 2024 – 06:30 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the signing on May 7 th , 2024 of an agreement to...

2023 ANNUAL RESULTS Growth in Core Business and strategic deployment Core business 1 revenues up 39% to €130m proprietary products account for 30% of revenues 38% of revenues generated outside France Resilient results within a strategic transformation phase Free cash flow of €26.4m Net financial debt reduced to €5.5m, with €89m cash position Paris, April 10, 2024 - 5.40pm - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences,...

MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023 Paris, le 30 octobre 2023 – 17h45 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à disposition du public et déposé auprès de l’Autorité des Marchés Financiers (AMF) le 30 octobre 2023 son rapport financier semestriel au 30 juin 2023. Le rapport financier semestriel peut être consulté sur le site Internet de la société...

Eurobio Scientific: GenDx reduces organ matching time to 3 hours Launch of NGS-Turbo, a unique test to match organs on Oxford Nanopore Technologies sequencing devices A valuable technological partnership with Oxford Nanopore Technologies A significant advance in HLA typing Paris, 17 th October 2023 – 5:40 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today announces the...

ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023 Strong growth in half-year core business revenues, up 37% Successful deployment of the Group's strategy: Share of proprietary products up, at 30% of revenues Continued internationalization, with 35% of revenues now generated outside of France Acquisition of DID in Italy effective as of July 1 st , 2023 Paris, July 2 4 , 2023 – 5: 45 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro...

2022 ANNUAL RESULT S Very strong performance and strengthening of the Core Business Core Business 1 revenue s up 15% to €93. 5 M (+53% since 2019) Increase in the share of proprietary products at 18% of revenue s International sales at 25% of revenue s After two exceptional years, decline in COVID business at 27% of revenue s in the second half, in line with expectations Margins maintained at high levels with EBITDA at €40. 5 M or 26.5% of revenue s Excellent cash generation capacity at €...

EUROBIO SCIENTIFIC FORMALISES THE APPOINTMENT OF ANNE-SOPHIE HERELLE AS GROUP CFO Paris, February 8 , 20 2 3 – 5: 45 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, formalises the appointment of Anne-Sophie Hérelle as Group Chief Financial Officer. Anne-Sophie Hérelle joined the company as Group CFO in October 2022, in charge of finance, investor relations and information systems. She is a member of the Group Executive...

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTIC S SPECIALIST • Acceleration of strategic plan confirming its positioning as a leader in the molecular diagnostics market • Acquisition of a 100% proprietary products portfolio • New high-level R&D and bioinformatics teams • Products marketed in many countries on several continents • Strong technological and commercial complementarities • Finalization of a €90 million bank loan Paris, October 3 , 202...

EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX, INTERNATIONAL HLA DIAGNOSTIC S SPECIALIST • Acceleration of strategic plan confirming its positioning as a leader in the molecular diagnostics market • Acquisition of a 100% proprietary products portfolio • New high-level R&D and bioinformatics teams • Products marketed in many countries on several continents • Strong technological and commercial complementarities Paris, August 17 , 202 2 – 6 : 00 p m Eurobio Scientific (...

Eurobio Scientific launches 2 new proprietary tests for the diagnosis of new variants of SARS-CoV-2 and Monkey pox EBX 048 : a routine COVID screening test that simultaneously detects and identifies the presence of Omicron BA.1, Omicron BA.2 and Omicron BA.4/BA.5 EBX 060 : routine viral test for the differential diagnosis of simian pox, varicella and measles viruses First French test for screening of Omicron BA.4/BA.5 variants or of the 3 viruses including simian pox, requiring only one reaction...

Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV Paris, Ju ne 1 3 , 20 2 2 – 5 : 45 p m Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces the acquisition of 100% of the share capital of Biomedical Diagnostics NV (“BMD”), a Belgian company specializing in the distribution of in vitro diagnostic tests in Benelux (Belgium, the Netherlands and...

CLOSING OF THE STRATEGIC PARTNERSHIP WITH NEXTSTAGE AM EurobioNext holding becomes Eurobio Scientific’s new reference shareholder with a 28.3% holding The « Pépites et Territoires » by AXA France investment program and NextStage (NEXTS) own 43.5% of EurobioNext Operation based on a unit price of 25.28 euros per Eurobio Scientific share Paris, May 18 , 2022 – 1 8 : 30 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and...

CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x , BA.2 and Delta variants of SARS-CoV-2 A r outine COVID screening test that simultaneously detects and identifies the presence of Omicron BA.x , Omicron BA.2 and screens for other Delta variants First CE marked French test for screening for Omicron and Delta variants requiring only one reaction and delivering a result in 45 minutes Paris, April 14 , 2022 – 8:00 a m Eurobio Scientific (FR0013240934,...

MAINTAINING HIGH LEVEL RESULTS IN 2021 Total turnover of €184.7m Growth in non-COVID activities (+14%) Strong EBITDA at €78m Increased cash generation at €66m (€55m in 2020) Cash position at €102m and decrease in financial debt (€11m) Acceleration of strategic deployment focused on proprietary products, international development, and new market segments Paris, April 6 , 20 2 2 – 7h30 Eurobio Scientific (FR0013240934, ALERS), a leading French group in specialty in vitro medical...

STRATEGIC PARTNERSHIP WITH NEXTSTAGE AM The reference shareholders of Eurobio Scientific join forces with NextStage AM and Nextstage SCA 1st investment under the “Pépites et Territoires” program by AXA France & NextStage AM in a holding company to be set up Operation based on a unit price of 25.28 euros per Eurobio Scientific share Strategic reinforcement to accelerate the growth of the Eurobio Scientific Group Paris, February 7 , 202 2 – 8 : 00a m Eurobio Scientific (FR0013240934, ALERS,...

EUROBIO SCIENTIFIC LAUNCHES THE EXCLUSIVE DISTRIBUTION OF THE FIRST SALIVA SELF-TEST FOR HIV TESTING IN FRANCE OraQuick®: first rapid saliva self-test for HIV screening for point-of-care biology, including pharmacies Paris, January 1 1 , 202 2 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in specialty in vitro medical diagnostics, announces that it entered into an exclusive distribution contract for the commercialization of OraQuick®, a saliva...

EUROBIO SCIENTIFIC MAKES A MINORITY INVESTMENT IN USENSE, A START-UP DEVELOPPING A MOBILE IN VITRO MEDICAL DEVICE FOR URIANALYSIS With this investment, the Group strengthens its offer in point of care medical biology and positions itself in the digitalization of diagnostics Paris, November 23, 20 2 1 – 6 : 1 5pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in the field of specialty in vitro medical diagnostics, announces today that it made a minority...

EUROBIO SCIENTIFIC RECEIVES A $ 430 ,000 MILESTONE PAYMENT FROM ALLERGAN Transition to clinical stage of a molecule derived from the former collaboration Paris, October 6 , 20 2 1 – 8 : 00 a m Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces today that it received from Allergan (now AbbVie) a milestone payment of US $ 430,000 as part of an IND submission to the US FDA for the transition to...

FIRST HALF TURNOVER REACHES € 95.7 MILLION, A 54% INCREASE Strong growth in traditional activities excluding COVID : + 31% at € 40.9 million Extension of the installed instrument park Continuation of the proprietary products development strategy Paris, Ju ly 2 6 , 2021 – 5 : 45 p m Eurobio Scientific ( FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated half-year turnover as at June 30, 2021. New...

Eurobio Scientific launches its COVID antigen self-test Paris, June 2 , 2021 – 5 : 45 p m Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in specialty in vitro medical diagnostics, announces the launch of its new proprietary test EBS 1005, an antigen self-test developed to identify the presence of the SARS-CoV-2 coronavirus by simple nasal sampling. An easy to use proprietary antigen self-test The proprietary EBS 1005 test received today an exemption from the...